DIGIFAB
Total Payments
$1.6M
Transactions
129
Doctors
55
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $245,032 | 15 | 2 |
| 2023 | $360,326 | 51 | 30 |
| 2022 | $322,126 | 15 | 4 |
| 2021 | $316,976 | 21 | 8 |
| 2020 | $253,207 | 8 | 0 |
| 2019 | $146,288 | 1 | 0 |
| 2018 | $812.18 | 18 | 14 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.5M | 36 | 92.2% |
| Consulting Fee | $96,919 | 31 | 5.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,878 | 10 | 1.8% |
| Food and Beverage | $1,571 | 51 | 0.1% |
| Travel and Lodging | $971.16 | 1 | 0.1% |
Payments by Type
Research
$1.5M
36 transactions
General
$128,339
93 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Single system double blinded trial to evaluate the effect of pre-operative treatment with digiFab to prevent post-operative actute kidney injury (AKI) in patients at high risk for AKI ungergoing cardiac graft surgery | BTG International, Inc. | $436,693 | 0 |
| Characteristics of Patients Presenting with Digoxin Toxicity and Outcomes of Patients Treated with the Digoxin Immune Fab | BTG International, Inc. | $239,736 | 0 |
| DIGIFAB | BTG International, Inc. | $209,707 | 0 |
| Effects of Digifab on renal function perioperatively | BTG International, Inc. | $198,193 | 0 |
| Preop DigiFab in CABG to reduce ouabain levels and prevent AKI | BTG International, Inc. | $146,288 | 0 |
| Utilization of Digoxin Immune Fab for Serious and Life-Threatening Digoxin Toxicity | BTG International, Inc. | $110,675 | 0 |
| Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI | BTG International, Inc. | $102,860 | 0 |
| DigiFab CABG-AKI | BTG International, Inc. | $43,500 | 0 |
| UMB - DigiFab Preclinical (Oubain assay) | BTG International, Inc. | $28,777 | 0 |
Top Doctors Receiving Payments for DIGIFAB — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Emergency Medicine | Huntsville, AL | $13.43 | 1 |
| , MD | Vascular & Interventional Radiology | Miami, FL | $12.57 | 1 |
| , MD | Vascular & Interventional Radiology | Saint Louis, MO | $12.57 | 1 |
| , MD | Diagnostic Radiology | Des Moines, IA | $12.57 | 1 |
| , M.D | Vascular & Interventional Radiology | Saint Louis, MO | $12.57 | 1 |
| , MD | Vascular & Interventional Radiology | Minneapolis, MN | $12.57 | 1 |
Ad
Manufacturing Companies
- BTG International, Inc. $1.6M
- EKOS Corporation $62.85
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 55
- Transactions 129
About DIGIFAB
DIGIFAB is a drug associated with $1.6M in payments to 55 healthcare providers, recorded across 129 transactions in the CMS Open Payments database. The primary manufacturer is BTG International, Inc..
Payment data is available from 2018 to 2024. In 2024, $245,032 was paid across 15 transactions to 2 doctors.
The most common payment nature for DIGIFAB is "Unspecified" ($1.5M, 92.2% of total).
DIGIFAB is associated with 9 research studies, including "Single system double blinded trial to evaluate the effect of pre-operative treatment with digiFab to prevent post-operative actute kidney injury (AKI) in patients at high risk for AKI ungergoing cardiac graft surgery" ($436,693).